Earlier work has demonstrated that serum autoantibodies from coeliac patients targeted against transglutaminase2 (TG2) inhibit in vitro angiogenesis. The aim of this study was to establish whether coeliac patient-derived monoclonalTG2-targeted antibodies produced by recombination technology exert similar anti-angiogenic effects to serum-derived coeliacautoantibodies. In addition, we studied whether the monoclonal patient autoantibodies modulate endothelial cell TG2 activityand whether such modulation is related to the anti-angiogenic effects. Material and methods. The influence of coeliacpatient-derived monoclonal TG2-targeted antibodies on endothelial cell tubule formation was studied using a threedimensionalangiogenic cell culture model. Endothelial cell TG2 enzymatic activity was determined by means of a live-cellenzyme-linked immunosorbent assay. Results. Coeliac patient-derived monoclonal TG2-targeted antibodies produced byrecombination technology inhibited endothelial tubule formation and enhanced the crosslinking activity of TG2. When thisenzymatic activity was inhibited using site-directed irreversible TG2 inhibitors in the presence of autoantibodies, in vitroangiogenesis reverted to the control level. Conclusions. Since we found a significant negative correlation between endothelialcell angiogenesis and TG2 activity, we suggest that the anti-angiogenic effects of coeliac patient-derived TG2-targetedautoantibodies are exerted by enhanced enzymatic activity of TG2.

Inhibition of transglutaminase 2 enzymatic activity ameliorates the anti-angiogenic effects of coeliac disease autoantibodies

SBLATTERO, DANIELE;MARZARI, ROBERTO;
2010-01-01

Abstract

Earlier work has demonstrated that serum autoantibodies from coeliac patients targeted against transglutaminase2 (TG2) inhibit in vitro angiogenesis. The aim of this study was to establish whether coeliac patient-derived monoclonalTG2-targeted antibodies produced by recombination technology exert similar anti-angiogenic effects to serum-derived coeliacautoantibodies. In addition, we studied whether the monoclonal patient autoantibodies modulate endothelial cell TG2 activityand whether such modulation is related to the anti-angiogenic effects. Material and methods. The influence of coeliacpatient-derived monoclonal TG2-targeted antibodies on endothelial cell tubule formation was studied using a threedimensionalangiogenic cell culture model. Endothelial cell TG2 enzymatic activity was determined by means of a live-cellenzyme-linked immunosorbent assay. Results. Coeliac patient-derived monoclonal TG2-targeted antibodies produced byrecombination technology inhibited endothelial tubule formation and enhanced the crosslinking activity of TG2. When thisenzymatic activity was inhibited using site-directed irreversible TG2 inhibitors in the presence of autoantibodies, in vitroangiogenesis reverted to the control level. Conclusions. Since we found a significant negative correlation between endothelialcell angiogenesis and TG2 activity, we suggest that the anti-angiogenic effects of coeliac patient-derived TG2-targetedautoantibodies are exerted by enhanced enzymatic activity of TG2.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11368/2304301
 Avviso

Registrazione in corso di verifica.
La registrazione di questo prodotto non è ancora stata validata in ArTS.

Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 12
social impact